Industria Farmacéutica y Psiquiatría

• Autores: Alberto Ortiz Lobo, Iván de la Mata Ruiz
• Localización: Revista de la Asociación Española de Neuropsiquiatría, ISSN 0211-5735, Vol. 23, Nº. 86, 2003, págs. 49-71
• Idioma: español
• DOI: 10.4321/s0211-57352003000200005
• Enlaces
  • Texto completo
• Dialnet Métricas: 14 Citas
• Referencias bibliográficas
  • 1. Healy D. The psychopharmacological era: notes towards a history. Journal of psychopharmacology 1990; 4(3): 152-167
  • 2. Shorther E. A history of Psychiatry.(1997) John & Wiley Inc. Ed. 1997. (Traducción española en J&C Ediciones Médicas S.L1999, Barcelona...
  • 3. Sachs RM, Dieck GS. (1989) A view from industry. En Strom BL. Pharmacoepidemiology. Churchill Livinstone, New York.
  • 4. Moncrieff J. An investigation into the precedents of modern drug treatment in psychiatry. History of Psychiatry 1999; 10: 475-490.
  • 5. Fernández-Liria A. Gestión del malestar y sociedad espectacular-mercantil. Sin publicar.
  • 6. Moynihan R, Smith R. Too much medicine? (editorial). BMJ 2002; 324:859-860.
  • 7. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 2002; 324: 886-891.
  • 8. O´Reilly B.There´s still gold in them thar pills. Fortune magazine, Lunes 23 de Julio de 2001.
  • 9. Gury M. IMS reports 12 percent growth in 2001 audited global pharmaceuticals sales. IMS Health 2002 http://www.ims-global.com/insight/news_story/0103/news_story_010314.htm
  • 10. Silva CD. Introducción al Seminario: Proyecto Goliat: La industria farmacéutica y su impacto en la prescripción de fármacos. En: http://www.edupsi.com/goliat.htm
  • 11. Scholdelmayer WS. Public citizen update: competition and pricing Iisues in the pharmaceutical Market. Prime Institute. University of Minnesota,...
  • 12. Soger A, Socolar D. Pharmaceutical marketing and research spending: the evidence does not support PhRMA´s claims. Presentado en: American...
  • 13. Prescription drugs and Mass Media adversiting. NIHCM,2001. http://www.nichm.org/DTCbcie/2001.pdf
  • 14. Bodenheimer T.Uneasy alliance: clínica investigators and the pharmaceutical industry. N Engl J Med 2000; 342: 1539-1544
  • 15. Esteve Soler J. La industria farmacéutica como la impulsora de la I+D en el sector sanitario. Revista de la administración sanitaria...
  • 16. Ferrán Mercadé M. La financiación de las sociedades científicas y la industria farmacéutica. Atención Primaria 2002;29:327-328
  • 17. Freemantle N Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant illness: a...
  • 18. Moncrieff J. Are antidepressants overrated? A review of metodological problems in antidepressant trials. J Nerv Ment Dis 2001; 189: 288-295
  • 19. Mata Ruiz I, Ortiz lobo A. Sesgos y dificultades en la investigación de los nuevos antipsicóticos. Rev Asoc Esp Neuropsiq; 2001, 79: 57-74.
  • 20. Smith R. Maintaining the integrity of the scientific record (editorial). BMJ 2001; 323:588
  • 21. Sponsorship, authorship, and accountability (editorial). The Lancet 2001; 358: 854-856.
  • 22. Just how tainted has medicine become? (editorial). The Lancet 2002; 359:
  • 23. Fernández Liria A. La nueva desmedicalización de la Psiquiatría. Psiquiatría Pública 1998; 10(2): 81-82.
  • 24. Scandal of scientists who take money for papers ghostwritten by drug companies. The Guardian 7 de Febrero 2002.
  • 25. Gilbody SM, Song F, Eastwood AJ, Sutton A. The causes, consequences and detection of publication bias in psychiatry. Acta Psychiatr Scand...
  • 26. Couhdry NK, Stelfox HT, Detsky AS. Relations between Authors of clinical practice guidelines and the pramaceutical industry. JAMA 2002;...
  • 27. Sheldon TA, Smith GD. Consensus conferences as drug promotion. The Lancet 1993; 334: 100-102.
  • 28. Interacctions with the pharmacuetical Industry: experiences and attitudes of psychiatric residents, interns and clerks. CMAJ, 1995; 153:553
  • 29. Wazana A. Physicians and the pharmaceutical industry. Is a gift ever just a gift? JAMA 2000; 283: 373-380
  • 30. Peay MY, Peay ER. The role of commercial sources in the adoption of a new drug. Soc Sci Med 1988; 26: 1183-1189.
  • 31. Lexchin J. Interactions between physicians and pharmaceutical industry. CMAJ 1993; 149: 1401-1407.)
  • 32. Haayer F. Rational prescribing and sources of information. Soc Sci Med 1982; 16: 2017-2023
  • 33. Wolfe SM. Why do American drug companies spend more than $12 billion a year pushing drugs? Is it education or promotion? J Gen Intern...
  • 34. Randall T. Kennedy hearings say no more free lunch — or much else — from drug firms. JAMA 1991; 265: 440-442
  • 35. Coyle SL. Physician-Industry relations. Part 1: individual physicians. Annals of Internal Medicine 2002; 136(5): 396-402.
  • 36. Komesaroff PA, Kerridge IH. Ethical issues concerning the relations between medical practitiones and the phramaceutical industry. The...
  • 37. Memoirs of methods used to sell drugs. MaLAM 1999; March/April Vol 17 Nº 3/ 4. http://www.healthyskepticism.org/editions/IN9903.htm
  • 38. Coyle SL. Physician-Industry relations. Part 2: Organizational issues. Annals of Internal Medicine 2002; 136(5): 403-406.
  • 39. Bowman MA. The impact of drug company funding on the content of continuing medical education. J Contin Educ Health Prof 1986; 6:66
  • 40. Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin...
  • 41. Tizón JL. Investigación y docencia en salus mental (I). Reflexiones del clínico antes de la autoinmolación. Rev Asoc Esp Neuropsiq 2001;...
  • 42. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998; 317: 1181-1184
  • 43. Van Praag HM. Inflationary tendencies in judging the yield of depresión research. Neuropsychobiology 1998; 37(3):130-141
  • 44. Friedberg M, Saffran B, Stinson T, Nelson W, Bennett C. Evaluation of conflict of interest in economic analyses of new drugs used in oncology....
  • 45. Fernández Liria A. Psiquiatría y psicofármacos en el nuevo siglo. Boletín de la AMSM 1999; (invierno):18-25
  • 46. Double D. The limits of psychiatry BMJ 2002;324:900-904
  • 47. El País. Así se vendió la «píldora de la timidez»
  • 48. Moncrieff J Psychiatric imperialism: the medicalisation of modern living. http://www.critpsynet.freeuk.com/sound.htm
  • 49. Ortiz Lobo A, García Moratalla B, Mata Ruiz I. Las consultas en un CSM de personas sin trastorno mental. Ponencia VI Congreso de la AMSM...